Liver Fibrosis - Pipeline Review, H2 2016

Publisher Name :
Date: 14-Sep-2016
No. of pages: 199
Inquire Before Buying

Global Markets Direct's, ‘Liver Fibrosis - Pipeline Review, H2 2016', provides an overview of the Liver Fibrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Liver Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Liver Fibrosis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Liver Fibrosis

  • The report reviews pipeline therapeutics for Liver Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved Liver Fibrosis therapeutics and enlists all their major and minor projects

  • The report assesses Liver Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news related to pipeline therapeutics for Liver Fibrosis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand important and diverse types of therapeutics under development for Liver Fibrosis

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Liver Fibrosis pipeline depth and focus of Indication therapeutics

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Liver Fibrosis - Pipeline Review, H2 2016

Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Liver Fibrosis Overview 9
Therapeutics Development 10
Pipeline Products for Liver Fibrosis - Overview 10
Pipeline Products for Liver Fibrosis - Comparative Analysis 11
Liver Fibrosis - Therapeutics under Development by Companies 12
Liver Fibrosis - Therapeutics under Investigation by Universities/Institutes 15
Liver Fibrosis - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Liver Fibrosis - Products under Development by Companies 18
Liver Fibrosis - Products under Investigation by Universities/Institutes 22
Liver Fibrosis - Companies Involved in Therapeutics Development 23
Advinus Therapeutics Ltd 23
Akarna Therapeutics Ltd. 24
Angion Biomedica Corp. 25
Asubio Pharma Co., Ltd. 26
aTyr Pharma, Inc. 27
Beijing Kawin Technology Share-Holding Co., Ltd. 28
BioLineRx, Ltd. 29
Bioneer Corporation 30
BiOrion Technologies B.V. 31
Bird Rock Bio, Inc. 32
Bristol-Myers Squibb Company 33
Cellmid Limited 34
ContraVir Pharmaceuticals, Inc. 35
Dicerna Pharmaceuticals, Inc. 36
Digna Biotech, S.L. 37
Dr. Falk Pharma GmbH 38
Dynavax Technologies Corporation 39
Evotec AG 40
Galectin Therapeutics, Inc. 41
Genfit SA 42
Gilead Sciences, Inc. 43
GNI Group Ltd. 44
HEC Pharm Co., Ltd. 45
Immuron Limited 46
Intercept Pharmaceuticals, Inc. 47
INVENT Pharmaceuticals, Inc. 48
Isarna Therapeutics GmbH 49
KineMed, Inc. 50
LG Life Science LTD. 51
Nitto Denko Corporation 52
Pfizer Inc. 53
Pharmaxis Limited 54
Promedior, Inc. 55
Promethera Biosciences S.A. 56
ProMetic Life Sciences Inc. 57
Ribomic Inc. 58
RXi Pharmaceuticals Corporation 59
Silence Therapeutics Plc 60
TCM Biotech International Corp 61
Vascular Biogenics Ltd. 62
Virobay Inc. 63
XTuit Pharmaceuticals, Inc. 64
Liver Fibrosis - Therapeutics Assessment 65
Assessment by Monotherapy Products 65
Assessment by Combination Products 66
Assessment by Target 67
Assessment by Mechanism of Action 71
Assessment by Route of Administration 74
Assessment by Molecule Type 76
Drug Profiles 78
ANG-3070 - Drug Profile 78
ANG-3281 - Drug Profile 79
Antisense RNAi Oligonucleotide for Liver Disease - Drug Profile 80
Antisense RNAi Oligonucleotide for Liver Diseases - Drug Profile 81
Antisense RNAi Oligonucleotide for Liver Fibrosis - Drug Profile 82
Antisense RNAi Oligonucleotide for Liver Fibrosis - Drug Profile 83
Antisense RNAi Oligonucleotide for Liver Fibrosis - Drug Profile 84
Antisense RNAi Oligonucleotide to Inhibit Beta Catenin for Liver Fibrosis - Drug Profile 85
Antisense RNAi Oligonucleotide to Inhibit HMGB1 for Liver Fibrosis - Drug Profile 86
ASB-14780 - Drug Profile 87
BL-1210 - Drug Profile 88
BMS-986171 - Drug Profile 89
BOT-162 - Drug Profile 90
BOT-191 - Drug Profile 91
CAB-102 - Drug Profile 92
CPI-43132 - Drug Profile 94
CT-140 - Drug Profile 97
DB-036 - Drug Profile 98
Drug to Inhibit Galectin-3 for Liver Fibrosis, Respiratory Disorder and Kidney Fibrosis - Drug Profile 99
Drugs for Tissue Fibrosis - Drug Profile 100
DV-1079 - Drug Profile 101
F-351 - Drug Profile 103
Gene Therapy for Liver Fibrosis - Drug Profile 105
GMCT-01 - Drug Profile 106
GRMD-02 - Drug Profile 110
GS-444217 - Drug Profile 121
HEC-585 - Drug Profile 122
HepaStem - Drug Profile 123
IMM-124E - Drug Profile 125
INT-767 - Drug Profile 128
INV-240 - Drug Profile 129
ISTH-0047 - Drug Profile 130
KW-0 - Drug Profile 132
KW-012 - Drug Profile 133
LC-280126 - Drug Profile 134
melittin - Drug Profile 135
Monoclonal Antibodies to Antagonize TGF-Beta Receptor Type-1 for HCV associated Liver Fibrosis - Drug Profile 136
MOR-8457 - Drug Profile 137
MRI-1867 - Drug Profile 138
ND-L02s0201 - Drug Profile 139
norursodeoxycholic acid - Drug Profile 141
noscapine - Drug Profile 142
PBI-4050 - Drug Profile 143
PRM-151 - Drug Profile 148
Proteins for Liver Fibrosis - Drug Profile 153
PXS-4820 - Drug Profile 154
PXS-5033A - Drug Profile 155
RBM-006 - Drug Profile 156
Recombinant MMP-9 Replacement for Liver Fibrosis, Pulmonary Fibrosis, Dupuytren Contracture, Peyronies Disease and Transplantation - Drug Profile 157
RXI-209 - Drug Profile 158
RYI-018 - Drug Profile 159
selonsertib - Drug Profile 160
selonsertib + simtuzumab - Drug Profile 161
Small Molecule for Liver Fibrosis - Drug Profile 162
Small Molecule for Liver Fibrosis - Drug Profile 163
Small Molecule to Agonize FXR for NASH and Liver Fibrosis - Drug Profile 164
Small Molecule to Antagonize AlphaVBetaI for Fibrosis - Drug Profile 165
Small Molecule to Antagonize GPR91 for Retinal Angiogenesis and Liver Fibrosis - Drug Profile 166
Small Molecules for Hepatic Fibrosis - Drug Profile 167
Small Molecules for Liver Fibrosis and Idiopathic Pulmonary Fibrosis - Drug Profile 168
Stem Cell Therapy for Fibrosis and Non-Alcoholic Steatohepatitis - Drug Profile 169
Stem Cell Therapy for Liver Fibrosis and Liver Cirrhosis - Drug Profile 170
TCM-808FB - Drug Profile 171
TGFTX-4 - Drug Profile 172
VB-201 - Drug Profile 173
VB-703 - Drug Profile 176
VBY-376 - Drug Profile 177
VBY-825 - Drug Profile 178
Liver Fibrosis - Dormant Projects 179
Liver Fibrosis - Discontinued Products 183
Liver Fibrosis - Product Development Milestones 184
Featured News & Press Releases 184
Appendix 193
Methodology 193
Coverage 193
Secondary Research 193
Primary Research 193
Expert Panel Validation 193
Contact Us 193
Disclaimer 194

List of Tables

Number of Products under Development for Liver Fibrosis, H2 2016 15
Number of Products under Development for Liver Fibrosis - Comparative Analysis, H2 2016 16
Number of Products under Development by Companies, H2 2016 17
Number of Products under Development by Companies, H2 2016 (Contd..1) 18
Number of Products under Development by Companies, H2 2016 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H2 2016 20
Comparative Analysis by Clinical Stage Development, H2 2016 21
Comparative Analysis by Early Stage Development, H2 2016 22
Products under Development by Companies, H2 2016 23
Products under Development by Companies, H2 2016 (Contd..1) 24
Products under Development by Companies, H2 2016 (Contd..2) 25
Products under Development by Companies, H2 2016 (Contd..3) 26
Products under Investigation by Universities/Institutes, H2 2016 27
Liver Fibrosis - Pipeline by Advinus Therapeutics Ltd, H2 2016 28
Liver Fibrosis - Pipeline by Akarna Therapeutics Ltd., H2 2016 29
Liver Fibrosis - Pipeline by Angion Biomedica Corp., H2 2016 30
Liver Fibrosis - Pipeline by Asubio Pharma Co., Ltd., H2 2016 31
Liver Fibrosis - Pipeline by aTyr Pharma, Inc., H2 2016 32
Liver Fibrosis - Pipeline by Beijing Kawin Technology Share-Holding Co., Ltd., H2 2016 33
Liver Fibrosis - Pipeline by BioLineRx, Ltd., H2 2016 34
Liver Fibrosis - Pipeline by Bioneer Corporation, H2 2016 35
Liver Fibrosis - Pipeline by BiOrion Technologies B.V., H2 2016 36
Liver Fibrosis - Pipeline by Bird Rock Bio, Inc., H2 2016 37
Liver Fibrosis - Pipeline by Bristol-Myers Squibb Company, H2 2016 38
Liver Fibrosis - Pipeline by Cellmid Limited, H2 2016 39
Liver Fibrosis - Pipeline by ContraVir Pharmaceuticals, Inc., H2 2016 40
Liver Fibrosis - Pipeline by Dicerna Pharmaceuticals, Inc., H2 2016 41
Liver Fibrosis - Pipeline by Digna Biotech, S.L., H2 2016 42
Liver Fibrosis - Pipeline by Dr. Falk Pharma GmbH, H2 2016 43
Liver Fibrosis - Pipeline by Dynavax Technologies Corporation, H2 2016 44
Liver Fibrosis - Pipeline by Evotec AG, H2 2016 45
Liver Fibrosis - Pipeline by Galectin Therapeutics, Inc., H2 2016 46
Liver Fibrosis - Pipeline by Genfit SA, H2 2016 47
Liver Fibrosis - Pipeline by Gilead Sciences, Inc., H2 2016 48
Liver Fibrosis - Pipeline by GNI Group Ltd., H2 2016 49
Liver Fibrosis - Pipeline by HEC Pharm Co., Ltd., H2 2016 50
Liver Fibrosis - Pipeline by Immuron Limited, H2 2016 51
Liver Fibrosis - Pipeline by Intercept Pharmaceuticals, Inc., H2 2016 52
Liver Fibrosis - Pipeline by INVENT Pharmaceuticals, Inc., H2 2016 53
Liver Fibrosis - Pipeline by Isarna Therapeutics GmbH, H2 2016 54
Liver Fibrosis - Pipeline by KineMed, Inc., H2 2016 55
Liver Fibrosis - Pipeline by LG Life Science LTD., H2 2016 56
Liver Fibrosis - Pipeline by Nitto Denko Corporation, H2 2016 57
Liver Fibrosis - Pipeline by Pfizer Inc., H2 2016 58
Liver Fibrosis - Pipeline by Pharmaxis Limited, H2 2016 59
Liver Fibrosis - Pipeline by Promedior, Inc., H2 2016 60
Liver Fibrosis - Pipeline by Promethera Biosciences S.A., H2 2016 61
Liver Fibrosis - Pipeline by ProMetic Life Sciences Inc., H2 2016 62
Liver Fibrosis - Pipeline by Ribomic Inc., H2 2016 63
Liver Fibrosis - Pipeline by RXi Pharmaceuticals Corporation, H2 2016 64
Liver Fibrosis - Pipeline by Silence Therapeutics Plc, H2 2016 65
Liver Fibrosis - Pipeline by TCM Biotech International Corp, H2 2016 66
Liver Fibrosis - Pipeline by Vascular Biogenics Ltd., H2 2016 67
Liver Fibrosis - Pipeline by Virobay Inc., H2 2016 68
Liver Fibrosis - Pipeline by XTuit Pharmaceuticals, Inc., H2 2016 69
Assessment by Monotherapy Products, H2 2016 70
Assessment by Combination Products, H2 2016 71
Number of Products by Stage and Target, H2 2016 73
Number of Products by Stage and Mechanism of Action, H2 2016 77
Number of Products by Stage and Route of Administration, H2 2016 80
Number of Products by Stage and Molecule Type, H2 2016 82
Liver Fibrosis - Dormant Projects, H2 2016 184
Liver Fibrosis - Dormant Projects (Contd..1), H2 2016 185
Liver Fibrosis - Dormant Projects (Contd..2), H2 2016 186
Liver Fibrosis - Dormant Projects (Contd..3), H2 2016 187
Liver Fibrosis - Discontinued Products, H2 2016 188

List of Figures

Number of Products under Development for Liver Fibrosis, H2 2016 15
Number of Products under Development for Liver Fibrosis - Comparative Analysis, H2 2016 16
Number of Products under Development by Companies, H2 2016 17
Comparative Analysis by Clinical Stage Development, H2 2016 21
Comparative Analysis by Early Stage Products, H2 2016 22
Assessment by Monotherapy Products, H2 2016 70
Number of Products by Top 10 Targets, H2 2016 72
Number of Products by Stage and Top 10 Targets, H2 2016 72
Number of Products by Top 10 Mechanism of Actions, H2 2016 76
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 76
Number of Products by Routes of Administration, H2 2016 79
Number of Products by Stage and Routes of Administration, H2 2016 79
Number of Products by Top 10 Molecule Types, H2 2016 81
Number of Products by Stage and Top 10 Molecule Types, H2 2016 81
  • Global Brachytherapy Afterloaders, Brachytherapy Seeds Market by Manufacturers, Regions, Type and Application, Forecast to 2021
    Published: 06-Dec-2016        Price: US 3480 Onwards        Pages: 118
    "Brachytherapy also known as internal radiotherapy, sealed source radiotherapy, curie therapy or endocurietherapy, is a form of radiotherapy where a sealed radiation source is placed inside or next to the area requiring treatment. Brachytherapy is commonly used as an effective treatment for cervical, prostate, breast, and skin cancer and can also be used to treat tumors in many other body sites. Brachytherapy Afterloaders, is kind of machine used in brachytherapy to deliverer radi......
  • Hypothyroidism - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 29
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypothyroidism - Pipeline Review, H2 2016, provides an overview of the Hypothyroidism (Hormonal Disorders) pipeline landscape.Hypothyroidism (underactive thyroid) is a condition in which thyroid gland doesn't produce enough of certain important hormones. Signs and symptom include fatigue, constipation, dry skin, puffy face, muscle weakness, muscle aches, tenderness and stiffness, pain and stiffness. Risk facto......
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 63
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Adrenoleukodystrophy - Pipeline Review, H2 2016, provides an overview of the Adrenoleukodystrophy (Genetic Disorders) pipeline landscape.Adrenoleukodystrophy is a disorder that occurs most often in males. It mainly affects the nervous system and the adrenal glands, which are small glands located on top of each kidney. Abetalipoproteinemia is also a kind of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-......
  • Behcet Disease - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 80
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Behcet Disease - Pipeline Review, H2 2016, provides an overview of the Behcet Disease (Immunology) pipeline landscape.Behcet disease (BEH-chets), sometimes called Behcet syndrome, Morbus Behçet, or Silk Road disease, is a rare immune-mediated systemic vasculitis. The more common symptoms include sores in the mouth and on the genitals (sex organs). More serious symptoms can include inflammation (swelling, heat,......
  • Secondary (Hypogonadotropic) Hypogonadism - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 63
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Secondary (Hypogonadotropic) Hypogonadism - Pipeline Review, H2 2016, provides an overview of the Secondary (Hypogonadotropic) Hypogonadism (Male Health) pipeline landscape.Hypogonadotropic hypogonadism (HH) is a form of hypogonadism that is due to a problem with the pituitary gland or hypothalamus. HH is caused by a lack of hormones that normally stimulate the ovaries or testes like gonadotropin-releasing hor......
  • Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 53
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline Review, H2 2016, provides an overview of the Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders) pipeline landscape.Homozygous familial hypercholesterolemia is a genetic disorder which is caused due to mutation from both parents. HoFH causes LDL cholesterol level to be very high. Symptoms include xanthelasmas, chest pain and sores on ......
  • United States, EU, Japan, China, India and Southeast Asia Cushings Syndrome Therapeutics Market Size, Status and Forecast 2021
    Published: 29-Nov-2016        Price: US 3300 Onwards        Pages: 91
    Notes: Production, means the output of Cushings Syndrome Therapeutics Revenue, means the sales value of Cushings Syndrome Therapeutics This report studies the global Cushings Syndrome Therapeutics market, analyzes and researches the Cushings Syndrome Therapeutics development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - Corcept Therapeutics - HRA Pharma......
  • Global Breast Implants and Sizer Market Research Report 2016
    Published: 28-Nov-2016        Price: US 2900 Onwards        Pages: 101
    Notes: Production, means the output of Breast Implants and Sizer Revenue, means the sales value of Breast Implants and Sizer This report studies Breast Implants and Sizer in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with Production, price, revenue and market share for each manufacturer, covering - Allergan - Natrelle - CEREPLAS - EuroSilicone -......
  • Europe Ozone Treatment Market Report 2016
    Published: 28-Nov-2016        Price: US 3900 Onwards        Pages: 112
    Notes: Sales, means the sales volume of Ozone Treatment Revenue, means the sales value of Ozone Treatment This report studies sales (consumption) of Ozone Treatment in Europe market, especially in Germany, UK, France, Russia, Italy, Benelux and Spain, focuses on top players in these countries, with sales, price, revenue and market share for each player in these Countries, covering - Kastner-Praxisbedarf GmbH - Herrmann Apparatebau GmbH - Humares ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs